|
COPYRIGHT 2003 Eli Research, Inc.
* CMS Settles Appeals Suit. Under a May 27 legal settlement, a dozen experts from the Medicare Coverage Advisory Commission will review whether Medicare should cover verteprofin for certain types of macular degeneration. CMS will have 60 days to accept, or to reject with a public explanation, the MCAC...
Read the full article for free courtesy of your local library.
|